BIOKIN PHARMACEUTICAL(SH:688506) Xin Lang Cai Jing·2025-12-29 02:09Core Viewpoint - Baili Tianheng's stock price has experienced significant fluctuations, with a year-to-date increase of 72.98%, but a recent decline of 5.24% over the last five trading days, indicating potential volatility in investor sentiment [1]. Group 1: Stock Performance - As of December 29, Baili Tianheng's stock price was 331.66 CNY per share, with a market capitalization of 136.93 billion CNY [1]. - The stock has seen a net outflow of 2.3351 million CNY in principal funds, with large orders showing a buy of 6.9057 million CNY and a sell of 12.8123 million CNY [1]. - The stock has declined by 11.36% over the past 20 days and 11.06% over the past 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Baili Tianheng reported a revenue of 2.066 billion CNY, a decrease of 63.52% year-on-year [2]. - The company recorded a net profit attributable to shareholders of -495 million CNY, reflecting a year-on-year decrease of 112.16% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 25.08% to 5,979, while the average circulating shares per person decreased by 20.05% to 17,208 shares [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with significant reductions in their holdings [3].